Cargando…

Lactobacillus casei Variety rhamnosus Probiotic Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a Syngeneic Colorectal Cancer Model

Adjuvant 5-fluorouracil (5-FU)-based chemotherapy, including FOLFOX (5-FU, leucovorin, and oxaliplatin), is recommended for colorectal cancer. However, intestinal mucositis remains a common adverse effect for which no effective preventive strategies are available. To develop a convenient and novel w...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Ching-Wei, Liu, Chia-Yuan, Lee, Hung-Chang, Huang, Yen-Hua, Li, Li-Hui, Chiau, Jen-Shiu Chiang, Wang, Tsang-En, Chu, Cheng-Hsin, Shih, Shou-Chuan, Tsai, Tung-Hu, Chen, Yu-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962742/
https://www.ncbi.nlm.nih.gov/pubmed/29867884
http://dx.doi.org/10.3389/fmicb.2018.00983
_version_ 1783324931393585152
author Chang, Ching-Wei
Liu, Chia-Yuan
Lee, Hung-Chang
Huang, Yen-Hua
Li, Li-Hui
Chiau, Jen-Shiu Chiang
Wang, Tsang-En
Chu, Cheng-Hsin
Shih, Shou-Chuan
Tsai, Tung-Hu
Chen, Yu-Jen
author_facet Chang, Ching-Wei
Liu, Chia-Yuan
Lee, Hung-Chang
Huang, Yen-Hua
Li, Li-Hui
Chiau, Jen-Shiu Chiang
Wang, Tsang-En
Chu, Cheng-Hsin
Shih, Shou-Chuan
Tsai, Tung-Hu
Chen, Yu-Jen
author_sort Chang, Ching-Wei
collection PubMed
description Adjuvant 5-fluorouracil (5-FU)-based chemotherapy, including FOLFOX (5-FU, leucovorin, and oxaliplatin), is recommended for colorectal cancer. However, intestinal mucositis remains a common adverse effect for which no effective preventive strategies are available. To develop a convenient and novel way to alleviate mucositis, we investigated the effect of Lactobacillus casei variety rhamnosus (Lcr35) on FOLFOX-induced mucosal injury. BALB/c mice subcutaneously injected with syngeneic CT26 colorectal adenocarcinoma cells were orally administered Lcr35 daily before, during, and after 5-day injection of FOLFOX regimen, for 14 days. The following methods were used: diarrhea score for toxicity, ELISA for cytokine production, histopathology for intestinal injury, immunohistochemistry for apoptosis/proliferation and regulatory proteins, RT-PCR for cytokine mRNA expression, and DNA sequencing for fecal gut microbiota. FOLFOX administration to colorectal cancer-bearing mice significantly inhibited tumor growth and the accompanying marked diarrhea and intestinal injury histologically characterized by the shortening of villi and destruction of intestinal crypts. Preventive administration of Lcr35 dose-dependently reduced the severity of diarrhea and intestinal mucositis without affecting the anti-tumor effect of FOLFOX. The numbers of apoptotic, NF-κB-, and BAX-activated cells increased after FOLFOX, and these responses were mitigated by Lcr35. TNF-α and IL-6 upregulation by FOLFOX treatment was attenuated by Lcr35. The fecal gut microbiota composition of Firmicutes and Bacteroidetes disturbed by FOLFOX was significantly reversed by Lcr35 toward a preferential profile. In conclusion, the oral probiotic Lcr35 prevented FOLFOX-induced intestinal mucositis in colorectal cancer-bearing mice. The putative mechanism might involve modulation of gut microbiota and proinflammatory responses with suppression of intrinsic apoptosis in intestinal injury.
format Online
Article
Text
id pubmed-5962742
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59627422018-06-04 Lactobacillus casei Variety rhamnosus Probiotic Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a Syngeneic Colorectal Cancer Model Chang, Ching-Wei Liu, Chia-Yuan Lee, Hung-Chang Huang, Yen-Hua Li, Li-Hui Chiau, Jen-Shiu Chiang Wang, Tsang-En Chu, Cheng-Hsin Shih, Shou-Chuan Tsai, Tung-Hu Chen, Yu-Jen Front Microbiol Microbiology Adjuvant 5-fluorouracil (5-FU)-based chemotherapy, including FOLFOX (5-FU, leucovorin, and oxaliplatin), is recommended for colorectal cancer. However, intestinal mucositis remains a common adverse effect for which no effective preventive strategies are available. To develop a convenient and novel way to alleviate mucositis, we investigated the effect of Lactobacillus casei variety rhamnosus (Lcr35) on FOLFOX-induced mucosal injury. BALB/c mice subcutaneously injected with syngeneic CT26 colorectal adenocarcinoma cells were orally administered Lcr35 daily before, during, and after 5-day injection of FOLFOX regimen, for 14 days. The following methods were used: diarrhea score for toxicity, ELISA for cytokine production, histopathology for intestinal injury, immunohistochemistry for apoptosis/proliferation and regulatory proteins, RT-PCR for cytokine mRNA expression, and DNA sequencing for fecal gut microbiota. FOLFOX administration to colorectal cancer-bearing mice significantly inhibited tumor growth and the accompanying marked diarrhea and intestinal injury histologically characterized by the shortening of villi and destruction of intestinal crypts. Preventive administration of Lcr35 dose-dependently reduced the severity of diarrhea and intestinal mucositis without affecting the anti-tumor effect of FOLFOX. The numbers of apoptotic, NF-κB-, and BAX-activated cells increased after FOLFOX, and these responses were mitigated by Lcr35. TNF-α and IL-6 upregulation by FOLFOX treatment was attenuated by Lcr35. The fecal gut microbiota composition of Firmicutes and Bacteroidetes disturbed by FOLFOX was significantly reversed by Lcr35 toward a preferential profile. In conclusion, the oral probiotic Lcr35 prevented FOLFOX-induced intestinal mucositis in colorectal cancer-bearing mice. The putative mechanism might involve modulation of gut microbiota and proinflammatory responses with suppression of intrinsic apoptosis in intestinal injury. Frontiers Media S.A. 2018-05-15 /pmc/articles/PMC5962742/ /pubmed/29867884 http://dx.doi.org/10.3389/fmicb.2018.00983 Text en Copyright © 2018 Chang, Liu, Lee, Huang, Li, Chiang Chiau, Wang, Chu, Shih, Tsai and Chen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Chang, Ching-Wei
Liu, Chia-Yuan
Lee, Hung-Chang
Huang, Yen-Hua
Li, Li-Hui
Chiau, Jen-Shiu Chiang
Wang, Tsang-En
Chu, Cheng-Hsin
Shih, Shou-Chuan
Tsai, Tung-Hu
Chen, Yu-Jen
Lactobacillus casei Variety rhamnosus Probiotic Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a Syngeneic Colorectal Cancer Model
title Lactobacillus casei Variety rhamnosus Probiotic Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a Syngeneic Colorectal Cancer Model
title_full Lactobacillus casei Variety rhamnosus Probiotic Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a Syngeneic Colorectal Cancer Model
title_fullStr Lactobacillus casei Variety rhamnosus Probiotic Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a Syngeneic Colorectal Cancer Model
title_full_unstemmed Lactobacillus casei Variety rhamnosus Probiotic Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a Syngeneic Colorectal Cancer Model
title_short Lactobacillus casei Variety rhamnosus Probiotic Preventively Attenuates 5-Fluorouracil/Oxaliplatin-Induced Intestinal Injury in a Syngeneic Colorectal Cancer Model
title_sort lactobacillus casei variety rhamnosus probiotic preventively attenuates 5-fluorouracil/oxaliplatin-induced intestinal injury in a syngeneic colorectal cancer model
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5962742/
https://www.ncbi.nlm.nih.gov/pubmed/29867884
http://dx.doi.org/10.3389/fmicb.2018.00983
work_keys_str_mv AT changchingwei lactobacilluscaseivarietyrhamnosusprobioticpreventivelyattenuates5fluorouraciloxaliplatininducedintestinalinjuryinasyngeneiccolorectalcancermodel
AT liuchiayuan lactobacilluscaseivarietyrhamnosusprobioticpreventivelyattenuates5fluorouraciloxaliplatininducedintestinalinjuryinasyngeneiccolorectalcancermodel
AT leehungchang lactobacilluscaseivarietyrhamnosusprobioticpreventivelyattenuates5fluorouraciloxaliplatininducedintestinalinjuryinasyngeneiccolorectalcancermodel
AT huangyenhua lactobacilluscaseivarietyrhamnosusprobioticpreventivelyattenuates5fluorouraciloxaliplatininducedintestinalinjuryinasyngeneiccolorectalcancermodel
AT lilihui lactobacilluscaseivarietyrhamnosusprobioticpreventivelyattenuates5fluorouraciloxaliplatininducedintestinalinjuryinasyngeneiccolorectalcancermodel
AT chiaujenshiuchiang lactobacilluscaseivarietyrhamnosusprobioticpreventivelyattenuates5fluorouraciloxaliplatininducedintestinalinjuryinasyngeneiccolorectalcancermodel
AT wangtsangen lactobacilluscaseivarietyrhamnosusprobioticpreventivelyattenuates5fluorouraciloxaliplatininducedintestinalinjuryinasyngeneiccolorectalcancermodel
AT chuchenghsin lactobacilluscaseivarietyrhamnosusprobioticpreventivelyattenuates5fluorouraciloxaliplatininducedintestinalinjuryinasyngeneiccolorectalcancermodel
AT shihshouchuan lactobacilluscaseivarietyrhamnosusprobioticpreventivelyattenuates5fluorouraciloxaliplatininducedintestinalinjuryinasyngeneiccolorectalcancermodel
AT tsaitunghu lactobacilluscaseivarietyrhamnosusprobioticpreventivelyattenuates5fluorouraciloxaliplatininducedintestinalinjuryinasyngeneiccolorectalcancermodel
AT chenyujen lactobacilluscaseivarietyrhamnosusprobioticpreventivelyattenuates5fluorouraciloxaliplatininducedintestinalinjuryinasyngeneiccolorectalcancermodel